Activity Overview

This activity includes four modules to help rheumatologists and non-rheumatology providers understand the reasons for low participation among minorities in lupus clinical trials.

Registration is complimentary.

Target Audience

Rheumatologists, primary care providers, dermatologists, nephrologists, advanced practice nurses, fellows in training, physician assistants, residents, students.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss clinical trials basics
• Recognize lupus symptoms and lupus-related health disparities
• Recognize the definition of a clinical trial referral and discuss the clinical trial referral process, as well as how clinical trials sites and providers can utilize the MIMICT model
• Identify communication strategies to build trust between patients, providers, and principal investigators
• Identify culturally-competent communication strategies to use when interacting with patients

CE & MOC Information

CME

ACCME Accreditation Statement

See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.

AMA Designation Statement

The American College of Rheumatology designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME credit must be claimed by May 2, 2027, at 11:59 PM ET.

MOC

MOC Recognition Statement: American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board. 

After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.

MOC points must be claimed by May 2, 2027, at 11:59 PM ET.

Financial Relationship Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

1. Advisor or review panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/research support
6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
7. Independent contractor
8. Executive role and/or ownership interest
9. Royalties and/or patent beneficiary
10. Intellectual property/patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Private investigator
13. Expert witness
14. Equity interest
15. Other: specify details 

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.

1. Allen Anandarajah, MD (Planner) – No relevant financial information to disclose
2. Saira Z. Sheikh, MD (Planner) – GSK², Aurinia Pharmaceuticals², AstraZeneca², Lilly USA², LLC, Biogen², Cabaletta Bio², Pfizer⁵
3. J. Chistopher Reed, JD (Planner) – GlaxoSmithKline²
4. Tessa R. Englund, PhD, MPH (Reviewer) – No relevant financial information to disclose
5. Rosalind Ramsey-Goldman, MD, DrPH (Planner) – Cabaletta², BMS², Exagen², Merck², Upstart Research Consulting², Biogen², Ampel Solutions²
6. Michelle Wimes, JD (Reviewer) – No relevant financial information to disclose

Acknowledgement of Commercial Support

This activity is supported by the U.S. Department of Health and Human Services, Office of Minority Health (HHS, OMH) with Grant Numbers 1 CPIMP171138 and 1 CPIMP18116. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the OMH/HHS or U.S. Government.

Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.